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Summary 
Autonomous release of hematopoietic growth factors may play a crucial role in the pathogene- 
sis of certain hematological malignancies. Because of its  cytokine synthesis-inhibiting action, 
interleukin 10 (IL-10) could be a potentially useful molecule to affect leukemic ceil growth in 
such disorders. Chronic myelomonocytic leukemia (CMML) cells spontaneously form myeloid 
colonies  (colony-forming units-granutocyte/macrophage)  in  methylceilulose,  suggesting  an 
autocrine growth factor-mediated mechanism. We studied the effect of recombinant human IL- 
10  (rhlL-10) on the in vitro growth of mononuclear cells obtained from peripheral blood or 
bone marrow of patients with CMML. IL-10 specifically binding to leukemic cells had a pro- 
found and dose-dependent inhibitory effect on autonomous in vitro growth of CMML cells. 
IL-10 significantly inhibited the spontaneous growth ofmyeloid colonies in methylcellulose in 
10/11  patients,  and  autonomous  CMML  cell  growth  in  suspension  in  5/5  patients  tested. 
Spontaneous colony growth from CMML cells was also markedly reduced by addition ofanti- 
granulocyte/macrophage colony-stimulating factor (GM-CSF) antibodies, but not by addi- 
tion of antibodies  against  G-CSF,  IL-3, or IL-6.  IL-10-induced suppression of CMML  cell 
growth was reversed by the addition of exogenous GM-CSF and correlated with a substantial 
decrease in GM-CSF production by leukemic cells, both at the mRNA and protein levels. Our 
data indicate that IL-10 profoundly inhibits the autonomous growth of CMML cells in vitro 
most likely through suppression  of endogenous GM-CSF  release.  This  observation suggests 
therapeutic evaluation ofrhlL-10 in patients with CMML. 
C 
hronic myelomonocytic leukemia  (CMML) 1 is a he- 
matopoietic malignancy of the elderly that is charac- 
terized by leukocytosis with  monocytes and  granulocytic 
ceils in all stages of development, marked dysmyelopoiesis, 
a chronic course,  and unresponsiveness to aggressive  che- 
motherapy  (1-3).  CMML  differs  from  chronic  myeloid 
leukemia in several ways, including cytologic criteria, lack 
of Philadelphia  chromosome,  and  as  we  have  originally 
shown,  spontaneous  colony formation by CMML cells  in 
semisolid medium (4). The growth of hematopoietic colo- 
nies  without  addition  of exogenous growth  factors raises 
the possibility that CMML cells secrete their own growth 
factors that might subsequently lead to the proliferation of 
leukemic cells  through an autocrine growth factor-medi- 
~Abbreviations used in this paper: BM, bone marrow; CMML, chronic  my- 
elomonocytic  leukemia; MNC, mononuclear  cell; PB, peripheral blood; 
P,T, reverse  transcription. 
ated mechanism in vitro and possibly also in vivo (5). Later 
work  by  others  confirmed  our  original  observation  and 
suggested  GM-CSF  and  IL-6 as  candidate  growth factors 
for CMML cells (6). 
IL-10 is a 35-kD protein, originally identified by virtue 
of its  ability  to  inhibit  cytokine synthesis  in  T  helper  1 
clones (7, 8). It is primarily produced by mononuclear cells 
(MNC;  9)  and  possesses  a  wide  range  of activities  on  a 
number of cell types, including B  ceils  (10),  T  cells  (11), 
NK cells (12),  mast cells (13),  neutrophils (14),  eosinophils 
(15),  and monocytes (16).  The main feature of this  cyto- 
kine is a suppressive effect on cytokine expression.  Thus, IL- 
10 profoundly suppresses  the induced production of IL-lo~, 
IL-113, IL-6, IL-8, TNF-o~, and GM-CSF by human mono- 
cytes (16) and mouse peritoneal macrophages (17). 
Because of its cytokine synthesis-inhibiting action, IL-10 
could  be  a  potentially  useful  molecule  in  hematological 
malignancies  in  which  autostimulatory  mechanisms  may 
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PB findings 
Patient  Age/sex  Duration  WBC  Hb  Plt  Mono  LDH  Lysozyme  Karyotype  CT 
mo  ￿  109~liter  g/dl  ￿  109~liter  U/liter  I~g/ml 
JL  55/F  15  160  9.3  125  17  658  49  45XX,-7  + 
PM  70/F  22  181  8.4  118  26  503  126  46XX,t2/11  + 
R.L  66/F  60  20  14.2  387  30  287  27  46XX  - 
MR_  68/M  1  55.8  9.9  130  23  1280  62  45XO  - 
ML  59/F  8  8.5  9.9  72  23  138  49  46XX  + 
HL  68/M  105  19.9  9.7  87  15  440  34  NA  + 
DH  88/F  5  7  10.0  101  27  520  114  NA  - 
MA  79/F  36  14.3  8.5  130  30  165  146  46XX  - 
WM  81/F  6  9.8  8.6  8  29  94  51  46XX  - 
FJ  83/M  1  39.8  9.9  13  55  373  106  NA  - 
KR.  80/M  180  22.4  14.7  345  12  246  32  NA  - 
CT, chemotherapy; Hb, hemoglobin; Mono, monocytes; NA, not available; Plt, platelets; WBC, white blood cells. 
play  a  crucial  role  in  pathogenesis.  Here,  we  investigated 
the  effect of IL-10  on  the  autonomous  in vitro growth  of 
MNC  from  patients  with  CMML.  We  found  that  IL-10 
profoundly  inhibits  the  spontaneous  proliferation  of CMML 
ceils in methylcellulose and in suspension,  most likely through 
suppression  of spontaneous  release of GM-CSF. 
Materials  and Methods 
Patients.  All 11  patients met the diagnostic criteria for CMML 
according to  the  FAB group,  i.e.,  dyspoietic features  of myelo- 
dysplastic  syndromes associated with a blood monocytosis >109/1, 
an  increase  in bone  marrow  (BM)  monocyte  precursors,  and  a 
blast cell percentage <5% in the peripheral blood (PB) and <30% 
in BM. Clinical and laboratory data of these patients are shown in 
Table  1.  In four patients,  cytoreductive chemotherapy was given 
before or at the time of the study. 
Preparation of Cells.  After informed consent, PB was collected 
into sterile tubes containing 4  ml EDTA. BM samples were ob- 
tained by aspiration into sterile tubes containing heparin with no 
preservative. PB MNC and BM MNC were harvested after a Ficoll- 
Hypaque gradient centrifugation (400 g, 40 min, 1.007 g/ml). 
Reagents.  Recombinant  human  IL-10  (rhlL-10;  specific 
activity =  1-2  X  106 U/mg) was kindly provided by Schering- 
Plough  Corp.  (Kenilworth,  NJ). A  neutralizing anti-IL-10 anti- 
body was obtained from R.&D Systems Europe Ltd.  (UK), anti- 
bodies directed against  G-CSF, GM-CSF,  IL-3,  IL-6, and rhlL-6 
were purchased from Genzyme Corp.  (Cambridge, MA), rhGM- 
CSF and rhlL-3 were kindly provided by Sandoz (Basel,  Switzer- 
land),  and  rhG-CSF  was  purchased  from  British  Biotechnoiogy 
(Oxan,  UK).  Cytokines were added  at the onset of the culture. 
The  neutralizing  antibody  against  IL-10  was  preincubated  with 
IL-10 for 2 h  at room temperature.  Neutralizing antibodies against 
G-CSF, GM-CSF, IL-3, and IL-6 were used as recommended by 
the manufacturer. 
CFU-GMAssay.  PB MNC  or BM MNC  were  cultured in 
0.9% methylcellulose, 30% FCS (INLIFE, Wiener Neudorf, Aus- 
tria),  and  IMDM  (Gibco, Paisley,  Scotland)  with or without the 
addition  of cytokines  or anticytokine  antibodies.  Cultures  were 
plated in triplicate at 10-100  ￿  103 MNC/ml. After a culture pe- 
riod of 14 d  (37~  5% CO  2, full humidity)  cultures were exam- 
ined under  an inverted microscope.  Aggregates with  at least 40 
cells were counted as CFU-GM. 
Suspension Cultures.  PB MNC from CMML patients were cul- 
tured  at  5  X  10 s per milliliter for 7  d  in  IMDM  supplemented 
with 30% FCS with or without IL-10. Cell numbers were deter- 
mined using a  hemocytometer.  For morphological examination, 
cytospins were stained by May-Grfinwald-Giemsa. 
RadiolabelingofrIL-lO.  IL-10  was  labeled  with  125I using 
standard  techniques  (18).  Briefly,  250  big IL-10  (nmol),  2  mCi 
12-~I-Nal, and  5  b~g lactoperoxidase were  added  into  a vial con- 
taining a magnetic stirrer. The reaction mixture was slowly stirred 
at pH 7  (0.01  M  balance phosphate buffer) for 10 min and there- 
after subjected to a preparative gradient HPLC (RP C18 column, 
MeCN gradient).  The column eluent was passed through a scin- 
tillation radioactivity detector and a UV (280 nm) detector in se- 
ries.  The system was calibrated with unlabeled IL-10 and allowed 
collection of pure radioiodinated IL-10, separated from unlabeled 
IL-10,  as  well  as  from  reagents  and  inorganic  iodine  species. 
12sI-IL-10  was  isolated  in  a  40%  yield  at  a  specific  activity  of 
2,000  Ci/mmol.  The  ~2sI-IL-10  product  fraction  was  stabilized 
by addition of 2% human serum albumin and analyzed by analytic 
HPLC (same system as the preparative one), paper electrophoresis 
(zone  electrophoresis on 3MM  paper  [Whatman  Chemical Co., 
Clifton,  NJ],  0.1  M  barbital  buffer,  pH  8.6,  field 300  V  for  10 
min),  and  TCA precipitation  (10%  final TCA).  1Kadiochemical 
purity was >97% and remained stable during >24 h. 
Binding Assay.  In saturation  studies, intact cells (5  ￿  10 s cells 
per tube) were incubated in the assay buffer containing 50 retool/ 
liter Tris-HC1 (pH 7.4)  and 5 mmol/liter MgC12 with increasing 
concentrations  of 12sI-IL-10  (0.01-25  nmol/liter) in the absence 
(total binding) and the presence of unlabeled IL-I(} (1  p, mol/liter, 
nonspecific  binding)  for  45  rain  at  4~  Displacement  studies 
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Figure  1.  Dose-dependent inhibitory effect  of lL-10  on spontaneous 
CFU-GM growth of CMML cells in patient JL. PB MNC were cultured 
in methylcellulose with medium alone or with increasing concentrations 
of IL-10.  Colony growth was assessed after  14  d.  Results represent the 
mean values from triplicates. 
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Figure  2.  Specificity of  IL-10-induced  inhibition of  spontaneous 
CFU-GM growth  of CMML cells in patient WM. PB MNC were cul- 
tured in methylcellutose  with medium alone, with 5 ng/ml IL-10, or with 
IL-10 plus a neutralizing antibody against IL-10. Colony growth was as- 
sessed after 14 d. Results represent the mean values +  SD from triplicates. 
were performed with 5 nmol/liter 12sI-IL-10  (total binding) and 
increasing concentrations of unlabeled IL-10 (0.01-1  txmol/liter, 
nonspecific binding). After incubation, the reaction mixture was 
diluted 1:10 with assay buffer (4~  and centrifuged (5,000 g,  10 
min,  4~  to  separate  the  membrane-bound from  free  ligand. 
The resulting pellet was washed twice in buffer and counted in a 
gamma counter for  1 min. Binding data were calculated accord- 
ing to Scatchard (19). 
Semiquantitative Reverse Transcriptase PCR (RT-PCR) Analysis of 
GM-CSF Transcripts.  107 PB MNC were cultured in suspension 
with or without IL-10 (10 ng/rnl) for 24 h. After incubation, cells 
were  washed  twice  in  diethylpyrocarbonate-treated water,  and 
107 cell aliquots were lysed by the addition of 1.6 ml RNAzol B 
(Biotecx, Houston, TX). Total RNA was extracted as described 
(20).  The  integrity of RNA  was  controlled  by  electrophoresis 
through  formaldehyde  agarose  gels.  High  quality  RNA  was 
quantitated by measuring absorbance at 260 nm, and 1 Ixg of total 
RNA was subjected to cDNA synthesis as previously described (21). 
For  semiquantitative analysis  of GM-CSF  mRNA,  an  RT- 
PCR  technique  that  allows  measurement  of relative  transcript 
levels was applied (22, 23). The oligonucleotide primer sequences 
for the amplification of GM-CSF were:  5'-CTGCTGCTGAG- 
ATGAATGAAACAG-3' and 5'-TGGACTGGCTCCCAGCAG- 
TCAAAG-3', which bracketed a  GM-CSF fragment of 286  bp 
(24).  PCR  amplification of ABL transcripts was  used as a  refer- 
ence to assess variations of total RNA or cDNA between samples. 
The primer sequences for amplification of ABL were as follows: 
5'-CAGCGGCCAGTAGCATCTGACTTTG-3' and  5'-CCA- 
TTTTTGGTTTGGGCATCACACCATTCC-3', resulting in the 
production ofa PCR fragment of 228 bp (21).  The linear ranges 
of PCR amplifications of GM-CSF and ABL were established for 
each patient as a function of cycle number and cDNA concentra- 
tions,  as  described  (22,  23).  Reaction  conditions included 3  Ixl 
cDNA,  20  pmol  of each  primer,  1.5  mM  MgC12,  200  txM  of 
each dNTP,  2.5  U  Ampli Taq DNA polymerase (Perkin-Elmer 
Cetus Corp., Norwalk, CT), and [32p]dCTP (150,000 cpm) in a 
50-p,1 reaction volume. The thermol cycling conditions were de- 
naturation at 94~  (1 rain), annealing at 60~  (1 rain), and exten- 
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sion at 72~  (2 rain), preceded by an initial denaturation step at 
94~  for 5 rain and followed by a terminal extension of 10 min at 
72~  The number of PCR cycles for amplification of GM-CSF 
or ABL transcripts was 32 cycles for each patient. Reaction prod- 
ucts were subjected to  6% polyacrylamide gels  (Novex,  San Di- 
ego, CA), and dried gels were exposed to XAR-5 films (Eastman 
Kodak, Rochester, NY) at -70~  for 12 h. 
For quantification of the PCR products incorporated, [32p]dCTP 
was measured on autoradiograms using an imaging densitorneter 
(model 670; Bio  Rad Laboratories,  Hercules,  CA)  and the  sys- 
tem's volume integration program (Bio Rad Gel DOC  1000 sys- 
tem, Molecular Analyst/PC software). Potential differences of to- 
tal  cellular  RNA/cDNA  in  PCR  analyses  were  corrected  by 
dividing GM-CSF values by the ABL value (mean value of six 
PCR  analyses).  The  relative  level  of GM-CSF  transcripts  was 
measured in all patient samples in three PCR analyses in duplicate 
using freshly synthesized cDNA. 
GM-CSF Assay.  PB MNC  from CMML patients were cul- 
tured at 5  X  105 per milliliter in IMDM supplemented with 30% 
FCS with or without IL-10, and the supernatants were collected 
at day 2, 5, and 7, respectively. GM-CSF contents in supernatants 
were  measured by  an immunoenzymetric assay  (EASIA;  Med- 
genix  Diagnostics,  Fleurus,  Belgium).  The  detection  limit  for 
GM-CSF was 3 pg/ml. 
Statistical Analysis.  Data were expressed as mean values -  SD. 
The Student's t-test was used to compare differences  with regard to 
CFU-GM growth and cell growth in suspension. The paired t test 
was used to test for significant differences  between GM-CSF tran- 
script levels in CMML cells treated with or without IL-10. P <0.05 
was considered statistically significant. 
Results  and  Discussion 
Inhibitory  Effect of lL- 10 on Spontaneous  Growth  of CMML 
Cells in Methylcellulose and Suspension.  As  has  been  found 
previously by us (4)  and by others (6), MNC  obtained from 
PB or BM of CMML  patients form a high number ofmye- Table 2.  Inhibitory  Effect of lL-10 on Spontaneous CFU-GM Growth in Methylcellulose in CMML Patients 
GFU-GM +  SD/dish 
MNC/dish  Percent of 
Patient  Source  X  103  Control  +IL-10  inhibition  P 
JL  PB  10  130.0 ~  12.5  22.3  ~  11.5  83  <0.001 
PM  PB  15  124.3 _+ 7.5  28.0  _+  14.9  77  <0.001 
RL  PB  100  23.7  -  2.9  9.3 +  4.2  61  <0.01 
MR  BM  50  77.7  -+- 1.5  1.0 +  1.0  99  <0.001 
ML  PB  34  75.0  +-  1.7  7.0  -+ 2.0  91  <0.001 
HL  PB  50  19.3 -+ 4.2  8.3 -+ 2.3  57  <0.05 
DH  PB  50  54.0  --_ 12.0  6.0 +  2.0  89  <0.005 
MA  PB  50  9.7 +_ 3.5  6.7 +  1.5  31  >0.05 
WM*  PB  20  154.7 _+ 23.5  6.0  +  1.0  96  <0.001 
FJ  PB  25  45.3  +- 6.1  13.0 -4- 6.9  71  <0.005 
KR  PB  16  130.0 +  1.4  3.0  -+ 2.7  98  <0.001 
PB MNC or BM MNC from CMML patients were cultured as described in Materials and Methods with or without 10 ng/ml IL-10 (* in patient 
WM, 5 ng/nd IL-10 was used). Colony growth was assessed after 14 d. Results represent mean values + SD from triplicates. 
loid colonies in methylcellulose in the  absence of exoge- 
nous growth factors. Treatment of CMML cell cultures with 
IL-10 resulted in a  profound and  dose-dependent inhibi- 
tion of autonomous CFU-GM growth (Fig.  1).  IL-10 at a 
concentration of 0.1  ng/ml  already  markedly  suppressed 
colony growth,  and  maximal inhibition was  observed  at 
concentrations of i  and 10 ng/ml, respectively. The effect 
of 10  ng/ml IL-10 on leukemic cell growth  was  investi- 
gated in PB MNC or BM MNC from 11  CMML patients 
(Table 2).  Because  of the  great  variation of autonomous 
CFU-GM growth between individuals, cell cultures from 
different patients had to be plated with different cell num- 
bers to allow reliable scoring of colony growth.  As shown 
in Table 2,  10 ng/ml IL-10 significantly inhibited autono- 
mous  formation  of  myeloid  colonies  in  10/11  patients 
tested.  In all patients, there was a mean inhibition by 78% 
ranging from 31  to  99%.  The  effect  was  specific,  since a 
neutralizing anti-IL-10 antibody was able to prevent IL-10- 
induced suppression of CFU-GM growth (Fig. 2). 
In five patients with CMML,  suspension cultures were 
performed using PB MNC. As shown in Fig. 3, cell numbers 
increased in the absence of exogenous growth factors after 
7  d  in all five patients tested.  IL-10 significantly decreased 
CMML  cell  growth  in  three  patients  and  completely 
prevented  cell  growth  in two  patients.  By  examining cell 
morphology  on  May-Griinwald-Giemsa-stained cytospins 
(Fig.  4),  it was found that  IL-10 cultures, as  compared to 
medium alone, contained more mature cells (both in terms 
of relative and absolute cell numbers), suggesting that IL-10 
had not only growth-inhibiting, but also some differentia- 
tion-inducing  activity. 
Specific  Binding  of Radiolabeled  IL-10  to  CMML  Cells. 
Since in CMML patients with marked leukocytosis PB MNC 
preparations contained only small amounts of normal cells 
as compared to malignant cells, it was unlikely that the in- 
hibitory effects of IL-10 on cell growth were mediated by 
normal lymphocytes and/or monocytes. To further prove 
the direct action oflL-10 on the leukemic clone, it was im- 
portant to  examine wether CMML  cells expressed recep- 
tors for IL-10. Cell preparations from three patients (FJ, JL, 
and PM)  containing 1>90%  malignant cells, as determined 
by morphological examination, were used for binding stud- 
ies with 12sI-IL-10.  A  typical binding isotherm is shown in 
Fig. 5. In all three patients, significant binding of 125I-IL-10 
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Figure 3.  Inhibitory effect of IL-10 on spontaneous proliferation of 
CMML cells in suspension  in five patients. PB MNC were cultured with 
medium alone or with 10 ng/ml IL-I0. Cell nmnbers were determined 
after 7 d. Results represent mean values -+ SD from triplicates. 
1380  Interleukin 10 Inhibits Chronic Myelomonocytic Leukemia Cell Growth Figure 4.  May-Grfinwald-Giemsa  staining of CMML cells cultured for 7 d with medium alone (A) or with 10 ng/ml IL-10 (B) in patient PM. 
to intact  cells was  found.  The  linear Scatchard  transforma- 
tion suggested  a  single class of specific binding sites.  CMML 
cells  of these  patients  expressed  5.6,  5.0,  and  5.2  X  104 
IL-10-binding  sites  per  cell  with  K a of  1.8,  1.2,  and  1.2 
nmol/liter,  respectively. The  corresponding  inhibitory con- 
stants  (IC50) were 2.1,  1.8,  and 2.4 nmol/1. 
Inhibitory Effect of Anti-GM-CSF Antibody on Autonomous 
CFU-GM Growthj~om CMML Cells.  To  elucidate the pos- 
sible mechanism  of the  inhibitory action  of IL-10,  we  first 
tried to identify the factor responsible for autonomous  col- 
ony growth  by adding neutralizing antibodies against GM- 
CSF, G-CSF, IL-3, and IL-6 to cell cultures from three pa- 
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Figure 5.  Binding of 12sI-IL-10 to CMML cells in pa- 
tient FJ. The left panel shows the saturation  curve and the 
right panel shows the Scatchard plot. Specific binding was 
determined as total binding -  nonspecific  binding. In this 
patient,  the  binding capacity amounted  to  93  fmol/106 
cells (i.e., 56,000 sites per cell) with a corresponding/Ca of 
1.8 nmol/liter. Control 
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Figure 6.  Effect of anti cytokine antibodies on spontaneous CFU-GM 
growth of CMML cells in three patients.  PB MNC were cultured with 
medium  alone  or with  antibodies against  GM-CSF,  G-CSF,  IL-3,  or 
IL-6,  respectively.  Colony growth was assessed after 14 d. Results repre- 
sent mean values -+ SD from triplicates, m, patient  JL; [], patient PM; [], 
patient DH. 
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Figure  7.  Effect  of exogenous growth factors on IL-10-induced sup- 
pression of CFU-GM growth from CMML cells. PB MNC were cultured 
in methylcellulose  with 10 ng/nfl IL-10 in the presence or absence of ex- 
ogenous GM-CSF (100 U/ml), G-CSF (100 U/re.l),  IL-3 (10 U/ml), and 
IL-6 (10 ng/ml), respectively.  Colony growth was assessed after 14 d. Re- 
sults represent mean values  +  SD from triplicates.  I,  Patient JL; ~,  pa- 
tient PM. 
tients with  excessive  colony  growth.  A  previous  study has 
suggested GM-CSF  and IL-6 as candidate growth factors in 
CMML,  since  both  cytokines  were  detectable  in  condi- 
tioned  media  from  CMML  ceils,  and  antibodies  against 
GM-CSF  and IL-6  could partially inhibit spontaneous col- 
ony  formation  by  CMML  cells  (6).  In  our  patients,  only 
antibody  against  GM-CSF,  however,  reproducibly  inhib- 
ited  autonomous  CFU-GM  growth,  suggesting  GM-CSF 
as a major autocrine growth factor (Fig.  6). 
Effect of Exogenous  Growth  Factors on IL-I0  Induced Sup- 
pression of CFU-GM Growth from CMML Cells.  The  anti- 
proliferative  action  of anti-GM-CSF  antibody  in  CMML 
cells and the fact that IL-10  has been shown  to  inhibit cy- 
tokine synthesis, including GM-CSF,  in human  monocytes 
Figure  8.  Semiquantitative 
RT-PCP,  analysis of GM-CSF 
transcript levels.  (A)  Autoradio- 
grams  showing incorporated ra- 
dioactivity  of amplification  prod- 
ucts  obtained  from  PB  MNC 
cultured  in  suspension  with  or 
without IL-10 for 24 h. (B) Au- 
toradiograms  showing ABL tran- 
scripts that served as a reference 
to correct for potential variations 
of RNA or cDNA samples.  (C) 
Corrected  GM-CSF  transcript 
levels  in  cultured  CMML  cells. 
Each patient sample was analyzed 
m  three radioactive  PCR analy- 
ses m duplicate  using freshly syn- 
thesized cDNA. The quantity, of 
32p  incorporated into  the  PCP, 
product was detennined by den- 
sitometric scanning of the auto- 
radiograms.  Results  were  cor- 
rected  by  dividing  GM-CSF 
values  by  the  mean  values  ob- 
tained  from  six  ABL  transcripts 
of that  cDNA.  The  results  are 
shown as mean values -+ SD. 
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Figure 9.  GM-CSF  levels in supernatants of CMML cell cultures with 
medium alone or with 10 ng/ml IL-10  in patient  JL (i) and patient PM ('). 
(16),  led  us  to  hypothesize  that  inhibition  of  CMML 
growth by IL-10 was secondary to IL-10-induced suppres- 
sion of endogenous GM-CSF release. If this was the case, 
one  would  expect  that  exogenous  addition  of GM-CSF 
could largely reverse growth inhibition  by IL-10. In con- 
trast,  restoration  of colony growth by exogenous  growth 
factors would not be observed if IL-10 had a direct cyto- 
toxic effect on CMML cells. In fact, exogenous GM-CSF was 
able to completely overcome IL-10-induced suppression in 
two patients tested (Fig. 7).  Not surprisingly, G-CSF, IL-3, 
or  IL-6  were  ineffective  or  only moderately effective in 
correcting IL-10-induced growth inhibition. 
Inhibitory Effect of lL-10 on GM-CSF Messenger RNA Ex- 
pression in CMML Cells.  Analyses of the effect oflL-10 on 
GM-CSF  expression in  CMML  cells  at the  mRNA level 
were  performed in  four patients,  GM-CSF  transcripts,  as 
measured  by  the  semiquantitative  RT-PCR  technique 
(22,  23),  were  already present  in  freshly isolated  CMML 
cells  and further increased in these  cells  after 24 h  of sus- 
pension culture with medium alone (not shown).  In com- 
parison,  ABL  transcripts,  which  served  as  a  control,  re- 
mained unchanged during culture. In the presence oflL-10 
(10  ng/ml),  GM-CSF  transcript  levels  after  24  h  were 
markedly decreased,  as  compared to  cells  kept in  suspen- 
sion  without  IL-10  (Fig.  8).  Fig.  8  C  shows  corrected 
GM-CSF mRNA levels in the four patients.  Comparison 
of corrected GM-CSF transcript levels of CMML cells cul- 
tured  with  and without  IL-10 revealed a mean decrease 
of 79% in patient PM  (P <0.0005),  68% in patient ML 
(P <0.0001),  83% in patient DH (P <0.005),  and 60% in 
patient MA (P <0.005), respectively, by IL-10. 
Inhibitory Effect of lL-lO on GMoCSF Production by CMML 
Cells.  To confirm the inhibitory effect oflL-10 on GM- 
CSF production in CMML cells at the protein level, super- 
natants  from CMML  cell  suspension  cultures  obtained at 
different time points were analyzed for GM-CSF by an im- 
munoenzymetric assay (EASIA) in two patients. As shown 
in Fig.  9, CMML cells cultured in medium alone secreted 
GM-CSF spontaneously, with levels peaking at day 2  and 
gradually declining thereafter. In contrast, GM-CSF secre- 
tion  by CMML  cells  was almost completely abrogated in 
the presence oflL-10 (10 ng/ml) at all time points studied. 
In summary, we demonstrate here a hitherto  unknown 
profound inhibitory effect oflL-10 on the in vitro growth of 
CMML cells. IL-10 not only inhibited growth of CFU-GM 
in semisolid medium, but also clearly inhibited the growth 
of CMML cells in suspension. IL-10 was remarkebly effec- 
tive in the majority of patients tested.  The demonstration 
of specific binding of IL-10 to CMML cells  suggests a di- 
rect effect of IL-10 on  the  leukemic  cell population,  Al- 
though  the  exact mechanism of the  inhibitory  action  of 
IL-10 on CMML cells remains to be shown, our data pro- 
vide  strong  evidence  that  a  modulation  of endogenous 
GM-CSF  release in  CMML  cells  by IL-IO  plays a  major 
role. Therefore, growth inhibition by IL-10 may represent 
a novel strategy to interrupt autostimnlatory loops in hema- 
tological malignancy.  Administration  of IL-10 as  a  thera- 
peutic option should be harmless to normal hematopoietic 
cells,  since we have not  observed any inhibitory effect of 
IL-10 on normal CD34 + cells (data not shown). 
Regardless of the mechanism involved the profound in- 
hibitory effect oflL-10 on CMML cell growth in vitro has 
clear clinical implication.  Currently, patients with CMML 
appear to have a poor prognosis with  conventional  cyto- 
toxic drugs  (3).  Recently,  IL-10 has been administered in 
healthy volunteers and serum levels of the cytokine that are 
effective in  vitro were  achieved at tolerable administered 
doses  (25).  Thus,  biologic chemotherapy of CMML with 
IL-10 is feasible and our findings provide experimental sup- 
port for clinical trials oflL-10 in patients with CMML. 
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